HC Wainwright Lifts Earnings Estimates for PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) – Analysts at HC Wainwright upped their Q3 2025 earnings estimates for PDS Biotechnology in a report issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.25) for the quarter, up from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($0.83) EPS.

Separately, Wall Street Zen lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $1.19 on Friday. The company has a quick ratio of 2.33, a current ratio of 2.92 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $55.49 million, a PE ratio of -1.29 and a beta of 0.95. PDS Biotechnology has a twelve month low of $0.85 and a twelve month high of $4.29. The company has a 50-day moving average price of $1.32 and a two-hundred day moving average price of $1.32.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, August 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP boosted its position in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after acquiring an additional 48,132 shares during the period. Jane Street Group LLC bought a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $58,000. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $26,000. Blair William & Co. IL boosted its position in shares of PDS Biotechnology by 63.3% in the first quarter. Blair William & Co. IL now owns 257,200 shares of the company’s stock valued at $306,000 after acquiring an additional 99,700 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after acquiring an additional 76,800 shares during the period. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.